111 related articles for article (PubMed ID: 24575772)
1. EGFR gene mutations in patients with adenosquamous lung carcinoma.
Powrózek T; Krawczyk P; Ramlau R; Sura S; Wojas-Krawczyk K; Kucharczyk T; Walczyna B; Szumiło J; Szyszka-Barth K; Milecki P; Barinow-Wojewódzki A; Milanowski J
Asia Pac J Clin Oncol; 2014 Dec; 10(4):340-5. PubMed ID: 24575772
[TBL] [Abstract][Full Text] [Related]
2. EGFR and KRAS mutations in Chinese patients with adenosquamous carcinoma of the lung.
Jia XL; Chen G
Lung Cancer; 2011 Dec; 74(3):396-400. PubMed ID: 21592614
[TBL] [Abstract][Full Text] [Related]
3. High frequency of epidermal growth factor receptor mutations with complex patterns in non-small cell lung cancers related to gefitinib responsiveness in Taiwan.
Huang SF; Liu HP; Li LH; Ku YC; Fu YN; Tsai HY; Chen YT; Lin YF; Chang WC; Kuo HP; Wu YC; Chen YR; Tsai SF
Clin Cancer Res; 2004 Dec; 10(24):8195-203. PubMed ID: 15623594
[TBL] [Abstract][Full Text] [Related]
4. Predictive and prognostic factors in second- and third-line erlotinib treatment in NSCLC patients with known status of the EGFR gene.
Krawczyk P; Kowalski DM; Krawczyk KW; Szczyrek M; Mlak R; Rolski A; Szudy A; Kieszko R; Winiarczyk K; Milanowski J; Krzakowski M
Oncol Rep; 2013 Sep; 30(3):1463-72. PubMed ID: 23783797
[TBL] [Abstract][Full Text] [Related]
5. Abnormalities of epidermal growth factor receptor in lung squamous-cell carcinomas, adenosquamous carcinomas, and large-cell carcinomas: tyrosine kinase domain mutations are not rare in tumors with an adenocarcinoma component.
Ohtsuka K; Ohnishi H; Fujiwara M; Kishino T; Matsushima S; Furuyashiki G; Takei H; Koshiishi Y; Goya T; Watanabe T
Cancer; 2007 Feb; 109(4):741-50. PubMed ID: 17238183
[TBL] [Abstract][Full Text] [Related]
6. First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations.
Sequist LV; Martins RG; Spigel D; Grunberg SM; Spira A; Jänne PA; Joshi VA; McCollum D; Evans TL; Muzikansky A; Kuhlmann GL; Han M; Goldberg JS; Settleman J; Iafrate AJ; Engelman JA; Haber DA; Johnson BE; Lynch TJ
J Clin Oncol; 2008 May; 26(15):2442-9. PubMed ID: 18458038
[TBL] [Abstract][Full Text] [Related]
7. The long-term survival of a patient with adenosquamous lung carcinoma harboring EGFR-activating mutations who was treated with gefitinib.
Iwanaga K; Sueoka-Aragane N; Nakamura T; Mori D; Kimura S
Intern Med; 2012; 51(19):2771-4. PubMed ID: 23037472
[TBL] [Abstract][Full Text] [Related]
8. EGFR Mutation status in Japanese lung cancer patients: genotyping analysis using LightCycler.
Sasaki H; Endo K; Konishi A; Takada M; Kawahara M; Iuchi K; Matsumura A; Okumura M; Tanaka H; Kawaguchi T; Shimizu T; Takeuchi H; Yano M; Fukai I; Fujii Y
Clin Cancer Res; 2005 Apr; 11(8):2924-9. PubMed ID: 15837743
[TBL] [Abstract][Full Text] [Related]
9. [The efficacy and influence factors analysis of EGFR TKIs on patients with lung adenosquamous carcinoma].
Zhou SY; Hu XS; Li JL; Wang Y; Liu YT; Xing PY; Yang JL; Lin H; Shi YK
Zhonghua Zhong Liu Za Zhi; 2018 Oct; 40(10):776-781. PubMed ID: 30392343
[No Abstract] [Full Text] [Related]
10. EGFR mutation status in tumour-derived DNA from pleural effusion fluid is a practical basis for predicting the response to gefitinib.
Kimura H; Fujiwara Y; Sone T; Kunitoh H; Tamura T; Kasahara K; Nishio K
Br J Cancer; 2006 Nov; 95(10):1390-5. PubMed ID: 17060940
[TBL] [Abstract][Full Text] [Related]
11. Use of cigarette-smoking history to estimate the likelihood of mutations in epidermal growth factor receptor gene exons 19 and 21 in lung adenocarcinomas.
Pham D; Kris MG; Riely GJ; Sarkaria IS; McDonough T; Chuai S; Venkatraman ES; Miller VA; Ladanyi M; Pao W; Wilson RK; Singh B; Rusch VW
J Clin Oncol; 2006 Apr; 24(11):1700-4. PubMed ID: 16505411
[TBL] [Abstract][Full Text] [Related]
12. [Epidermal growth factor receptor gene mutations and clinicopathologic correlation in 309 patients with non-small cell lung cancer].
Feng Q; Li XH; Chen Z; He JS; Wang CX; Zhou LX; Xue WC
Zhonghua Bing Li Xue Za Zhi; 2011 Oct; 40(10):660-3. PubMed ID: 22321542
[TBL] [Abstract][Full Text] [Related]
13. Specific EGFR mutations predict treatment outcome of stage IIIB/IV patients with chemotherapy-naive non-small-cell lung cancer receiving first-line gefitinib monotherapy.
Yang CH; Yu CJ; Shih JY; Chang YC; Hu FC; Tsai MC; Chen KY; Lin ZZ; Huang CJ; Shun CT; Huang CL; Bean J; Cheng AL; Pao W; Yang PC
J Clin Oncol; 2008 Jun; 26(16):2745-53. PubMed ID: 18509184
[TBL] [Abstract][Full Text] [Related]
14. Gefitinib (ZD1839): therapy in selected patients with non-small cell lung cancer (NSCLC)?
Dongiovanni D; Daniele L; Barone C; Dongiovanni V; Fissore C; Sapino A; Macrì L; Bussolati G; Buffoni L; Gaspari F; Grillo R; Birocco N; Addeo A; Ciuffreda L; Schena M
Lung Cancer; 2008 Jul; 61(1):73-81. PubMed ID: 18243402
[TBL] [Abstract][Full Text] [Related]
15. Correlations of EGFR mutations and increases in EGFR and HER2 copy number to gefitinib response in a retrospective analysis of lung cancer patients.
Pugh TJ; Bebb G; Barclay L; Sutcliffe M; Fee J; Salski C; O'Connor R; Ho C; Murray N; Melosky B; English J; Vielkind J; Horsman D; Laskin JJ; Marra MA
BMC Cancer; 2007 Jul; 7():128. PubMed ID: 17626639
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic efficacy of gefitinib and erlotinib in patients with advanced lung adenosquamous carcinoma.
Song Z; Lin B; Shao L; Zhang Y
J Chin Med Assoc; 2013 Sep; 76(9):481-5. PubMed ID: 23769878
[TBL] [Abstract][Full Text] [Related]
17. Gefitinib-sensitive mutations of the epidermal growth factor receptor tyrosine kinase domain in chinese patients with non-small cell lung cancer.
Mu XL; Li LY; Zhang XT; Wang MZ; Feng RE; Cui QC; Zhou HS; Guo BQ
Clin Cancer Res; 2005 Jun; 11(12):4289-94. PubMed ID: 15958609
[TBL] [Abstract][Full Text] [Related]
18. Phase II prospective study of the efficacy of gefitinib for the treatment of stage III/IV non-small cell lung cancer with EGFR mutations, irrespective of previous chemotherapy.
Sunaga N; Tomizawa Y; Yanagitani N; Iijima H; Kaira K; Shimizu K; Tanaka S; Suga T; Hisada T; Ishizuka T; Saito R; Dobashi K; Mori M
Lung Cancer; 2007 Jun; 56(3):383-9. PubMed ID: 17368623
[TBL] [Abstract][Full Text] [Related]
19. Clinical outcomes after first-line EGFR inhibitor treatment for patients with NSCLC, EGFR mutation, and poor performance status.
Okuma Y; Hosomi Y; Nagamata M; Yamada Y; Sekihara K; Kato K; Hishima T; Okamura T
Anticancer Res; 2013 Nov; 33(11):5057-64. PubMed ID: 24222150
[TBL] [Abstract][Full Text] [Related]
20. Mutations of epidermal growth factor receptor of non-small cell lung cancer were associated with sensitivity to gefitinib in recurrence after surgery.
Kondo M; Yokoyama T; Fukui T; Yoshioka H; Yokoi K; Nagasaka T; Imaizumi K; Kume H; Hasegawa Y; Shimokata K; Sekido Y
Lung Cancer; 2005 Dec; 50(3):385-91. PubMed ID: 16140420
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
